-
-
-
Latest Results of Serplulimab in Lung and Gastrointestinal Cancer Released at ASCO 2025
2025-06-01
Shanghai, China, June 1, 2025 - Shanghai Henlius Biotech, Inc. (2696.HK) announced that the latest results from over ten studies on lung and gastrointestinal cancer of Henlius’ self-developed innovative anti-PD-1 monoclonal antibody (mAb) HANSIZHUANG (serplulimab, trade name: Hetronifly® in Europe) were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. HANSIZHUANG is the first anti-PD-1 mAb for the first-line treatment of SCLC and has been approved in over 30 countries and regions including China, Europe and Southeast Asia.
-
-
-
-
Fosun Pharma’s Self-Developed Innovative Drug Luvometinib Tablet Approved in China
2025-05-29
(May 29, 2025, Shanghai, China) — On 29 May, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; Stock Code: 600196.SH, 02196.HK), announced that its self-developed innovative drug Luvometinib Tablets (Chinese trade name:复迈宁®, project no.: FCN-159, the “New Drug”) has been officially approved for marketing by the National Medical Products Administration (NMPA). As a highly selective MEK1/2 inhibitor, the approved indication is the treatment of adult patients with Langerhans cell histiocytosis (LCH) and histiocytic neoplasms and the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection. The approval of the New Drug addresses unmet treatment needs in rare tumors and provides new treatment options for patients.
-
-
-
-
Henlius Receives Orphan Drug Designation for Its Innovative Anti-HER2 mAb HLX22 in the European Union for Gastric Cancer
2025-05-26
Shanghai, China, May 26, 2025 - Shanghai Henlius Biotech, Inc. (2696.HK) announced that the European Commission (EC) has granted Orphan Drug Designation (ODD) for HLX22, the company's innovative anti-HER2 monoclonal antibody (mAb) for the treatment of gastric cancer. At present, HLX22 is the world's first anti-HER2-targeted therapy to receive ODD approvals from both the FDA and the EC, suggesting its significant therapeutic potential in the treatment of gastric cancer.
-
-
-
-
Henlius Included in MSCI Global Small Cap Indexes, Reinforcing Its Position in Global Capital Markets
2025-05-15
Shanghai, China, May 14, 2025 - Shanghai Henlius Biotech, Inc. (2696.HK) announced that it has been included in the MSCI Global Small Cap Indexes following the results of the MSCI Equity Indexes May 2025 Index Review. The inclusion will be implemented as of the close of May 30, 2025.
-
-
-
-
Fosun Pharma’s Self-Developed Innovative Drug FCN-159 Tablet Granted Breakthrough Therapy Designation for the Treatment of Children with Langerhans Cell Histiocytosis
2025-05-12
On 12 May 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) announced that the self-developed innovative drug FCN-159 tablets (Luvometinib tablets, hereinafter the “New Drug”) has been granted breakthrough therapy designation for the treatment of children with Langerhans cell histiocytosis by the National Medical Products Administration (the “NMPA”). Currently, the New Drug is at the stage of Phase II clinical trial in Chinese Mainland.
-
-
-
-
Fosun Health and Prudential Collaborate to Establish a New Direct Payment Model for Medical Services in the Greater Bay Area
2025-05-12
As integration progresses within the Guangdong-Hong Kong-Macao Greater Bay Area, cross-border mobility and demand for medical services continue to rise. In recent years, residents have shown increasing concern for “seamless healthcare access”, “high-quality medical services”, and “direct payment options for medical expenses”.
-
-
-
-
Fosun Tourism Group Sees Full Occupancy across Resorts during May Day Holiday
2025-05-06
During the May Day holiday, domestic travel consumption surged, with Fosun Tourism Group’s vacation products achieving full occupancy across multiple resorts and destinations, solidifying its leadership in the leisure travel sector
-
-
-
-
Henlius Enters into License Agreement with Sandoz for Proposed Ipilimumab Biosimilar
2025-04-29
On April 29, 2025, Shanghai Henlius Biotech, Inc. (2696.HK) announced a licensing agreement with Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in generic and biosimilar medicines, granting exclusive commercialization rights for its self-developed ipilimumab biosimilar HLX13 in the United States, 42 European countries and regions, Japan, Canada, and Australia.
-
-
-
-
Fakeeh Care Group and Fosun Pharma Forge Strategic Partnership
2025-04-28
Fakeeh Care Group has announced a strategic partnership with Fosun Pharma, a leading innovation-driven global healthcare company operating in the fields of pharmaceuticals, medical devices & diagnostics, and healthcare services. This partnership is part of Fakeeh Care Group’s ambitious vision to accelerate healthcare innovation in Saudi Arabia and align with the Saudi Vision 2030.
-